Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28287137 | 0.97 | MAPT (0.42) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL2844045 | 0.83 | MAPT (0.43) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL28237924 | 0.79 | MAPT (0.41) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL7455288 | 0.79 | MMP1 (0.46) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL9518240 | 0.79 | GAA (0.41) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL1276983 | 0.77 | MAPT (0.46) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL29727668 | 0.74 | MAPT (0.45) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL11531391 | 0.74 | MAPT (0.45) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL38651931 | 0.73 | — | — | |
| SCHEMBL329843 | 0.72 | MMP1 (0.50) | MAPTGAAMMP1MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080571-A | Weather-resistant polyoxymethylene automobile sun visor material and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122011028-A | Method for efficiently preparing various substituted chiral phosphoramides | 上海交通大学 | 2026-05-12 | — | — | CN | claimed |
| WO-2024137495-A1 | FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | NAVINTA, LLC (US) | 2024-06-27 | — | — | WO | claimed |
| CN-114643075-B | Catalyst for synthesizing alkylene carbonate, and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-113999270-B | Method for synthesizing cytidine diphosphate | 新乡拓新药业股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-113999270-A | Method for synthesizing cytidine diphosphate | 新乡拓新药业股份有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-105732752-A | Citicoline and synthetic method thereof | 新乡学院 | 2016-07-06 | — | — | CN | claimed |
| CN-105693798-A | Citicoline and synthesizing method of citicoline not using phosphocholine chloride calcium | 新乡学院 | 2016-06-22 | — | — | CN | claimed |
| CN-122103207-A | Chiral morpholino phosphoryl chloride monomer and preparation method and application thereof | — | 2026-05-29 | — | — | CN | disclosed |
| CN-122103207-A | Chiral morpholino phosphoryl chloride monomer and preparation method and application thereof | — | 2026-05-29 | — | — | CN | disclosed |
| CN-122080571-A | Weather-resistant polyoxymethylene automobile sun visor material and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122011028-A | Method for efficiently preparing various substituted chiral phosphoramides | 上海交通大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-118581179-A | Method for synthesizing citicoline sodium by catalyzing cytidine in one pot by multi-enzyme system | 深圳华酶生物科技有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114643075-B | Catalyst for synthesizing alkylene carbonate, and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | MAPT 2188/4885GAA 2322/4885MMP1 4445/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | MAPT 2633/4885GAA 77/4885MMP1 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.